de Avila R, Muller I, Barlow H, Middleton A, Theiventhran M, Basili D
Front Toxicol. 2025; 7:1426132.
PMID: 40061084
PMC: 11885506.
DOI: 10.3389/ftox.2025.1426132.
Yellepeddi V, Hunt J, Green D, McKnite A, Whelan A, Watt K
CPT Pharmacometrics Syst Pharmacol. 2024; 13(9):1542-1553.
PMID: 39033462
PMC: 11533098.
DOI: 10.1002/psp4.13199.
Jeong K, Chang J, Park S, Kim J, Jeon S, Kim D
Antiviral Res. 2022; 209:105473.
PMID: 36435212
PMC: 9682871.
DOI: 10.1016/j.antiviral.2022.105473.
Algharably E, Di Consiglio E, Testai E, Pistollato F, Mielke H, Gundert-Remy U
Front Toxicol. 2022; 4:885843.
PMID: 35924078
PMC: 9340473.
DOI: 10.3389/ftox.2022.885843.
Chokesuwattanaskul R, Shah N, Chokesuwattanaskul S, Liu Z, Thakur R
J Innov Card Rhythm Manag. 2020; 11(4):4054-4061.
PMID: 32368381
PMC: 7192149.
DOI: 10.19102/icrm.2020.110403.
Benefit-risk assessment of dronedarone in the treatment of atrial fibrillation.
Adlan A, Lip G
Drug Saf. 2013; 36(2):93-110.
PMID: 23329540
DOI: 10.1007/s40264-012-0012-8.
Torsade de Pointes and Persistent QTc Prolongation after Intravenous Amiodarone.
Kotsia A, Dimitriadis G, Baltogiannis G, Kolettis T
Case Rep Med. 2012; 2012:673019.
PMID: 22474460
PMC: 3303706.
DOI: 10.1155/2012/673019.
Amiodarone for the treatment and prevention of ventricular fibrillation and ventricular tachycardia.
Van Herendael H, Dorian P
Vasc Health Risk Manag. 2010; 6:465-72.
PMID: 20730062
PMC: 2922307.
DOI: 10.2147/vhrm.s6611.
Therapeutic drug monitoring of antiarrhythmic drugs.
Jurgens G, Graudal N, Kampmann J
Clin Pharmacokinet. 2003; 42(7):647-63.
PMID: 12844326
DOI: 10.2165/00003088-200342070-00004.
Inhibitory effects of amiodarone and its N-deethylated metabolite on human cytochrome P450 activities: prediction of in vivo drug interactions.
Ohyama K, Nakajima M, Suzuki M, Shimada N, Yamazaki H, Yokoi T
Br J Clin Pharmacol. 2000; 49(3):244-53.
PMID: 10718780
PMC: 2014912.
DOI: 10.1046/j.1365-2125.2000.00134.x.
Amiodarone in a newborn with ventricular tachycardia and an intracardiac tumor: adjusting the dose according to an individualized dosing regimen.
Bouillon T, Schiffmann H, Bartmus D, Gundert-Remy U
Pediatr Cardiol. 1996; 17(2):112-4.
PMID: 8833497
DOI: 10.1007/BF02505094.
Class III antiarrhythmics in overdose. Presenting features and management principles.
Leatham E, Holt D, McKenna W
Drug Saf. 1993; 9(6):450-62.
PMID: 8129865
DOI: 10.2165/00002018-199309060-00008.
New antiarrhythmic drugs in pediatric use: amiodarone.
Paul T, Guccione P
Pediatr Cardiol. 1994; 15(3):132-8.
PMID: 8047495
DOI: 10.1007/BF00796325.
Serum concentrations of amiodarone during long term therapy. Relation to dose, efficacy and toxicity.
Staubli M, BIRCHER J, Galeazzi R, REMUND H, STUDER H
Eur J Clin Pharmacol. 1983; 24(4):485-94.
PMID: 6861863
DOI: 10.1007/BF00609891.
Intravenous amiodarone in atrial fibrillation complicating myocardial infarction.
Barnett D, Akhtar N, Hudson S
Br Med J (Clin Res Ed). 1982; 284(6318):823-4.
PMID: 6802243
PMC: 1496420.
DOI: 10.1136/bmj.284.6318.823-d.
Mass spectrometric identification of amiodarone N-monodesethyl metabolite and application of an HPLC method to a pharmacokinetic study.
Marchiset D, Aubert C, Sumirtapura Y, Egre A, Cano J
Eur J Drug Metab Pharmacokinet. 1984; 9(2):123-8.
PMID: 6745303
DOI: 10.1007/BF03189615.
Amiodarone kinetics after single i.v. bolus and multiple dosing in healthy volunteers.
Riva E, Aarons L, Latini R, Neyroz P, Urso R
Eur J Clin Pharmacol. 1984; 27(4):491-4.
PMID: 6519158
DOI: 10.1007/BF00549600.
Clinical pharmacokinetics of the newer antiarrhythmic agents.
Gillis A, Kates R
Clin Pharmacokinet. 1984; 9(5):375-403.
PMID: 6437721
DOI: 10.2165/00003088-198409050-00001.
Reliability of antiarrhythmic drug plasma concentration monitoring.
Follath F, Ganzinger U, Schuetz E
Clin Pharmacokinet. 1983; 8(1):63-82.
PMID: 6404580
DOI: 10.2165/00003088-198308010-00004.
Clinical pharmacokinetics of amiodarone.
Latini R, Tognoni G, Kates R
Clin Pharmacokinet. 1984; 9(2):136-56.
PMID: 6370540
DOI: 10.2165/00003088-198409020-00002.